🔎 Trials Near Me

Utama › Leukemia Limfoblastik Akut › Illinois › Chicago

Kajian klinikal Leukemia Limfoblastik Akut di Chicago, IL

19 kajian untuk Leukemia Limfoblastik Akut sedang mencari peserta di lokasi dalam dan sekitar Chicago (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
  • Mount Sinai Hospital Medical Center, Chicago
  • John H Stroger Jr Hospital of Cook County, Chicago
  • University of Illinois, Chicago
  • dan 1 lagi
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Mengambil pesertaFasa 1/2
  • The University of Chicago Medical Center, Chicago
30 Days · Semua jantina · Dikemas kini 16 Sep 2026 · NCT04065399

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Mengambil pesertaFasa 1/2
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Sehingga umur 22 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04726241

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

Mengambil pesertaFasa 2
  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Umur 7 hingga 25 · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT05082519

A Study of CTD402 in T-ALL/LBL Patients

Mengambil pesertaFasa 1/2
  • University of Chicago, Chicago
Umur 1 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT07070219

Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

Mengambil pesertaKajian pemerhatian
  • The University of Chicago, Chicago
1 Day – 17 Years · Semua jantina · Dikemas kini 14 Ogo 2026 · NCT06274788

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

Mengambil pesertaFasa 1/2
  • Research Site, Chicago
Umur 12 ke atas · Semua jantina · Dikemas kini 13 Jul 2026 · NCT07109219

Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia

Mengambil peserta
  • University of Chicago Medicine Comprehensive Cancer Center, Chicago
Umur 15 ke atas · Semua jantina · Dikemas kini 10 Jul 2026 · NCT06446661

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Mengambil pesertaKajian pemerhatian
  • Northwestern Memorial Hospital, Chicago
  • Rush University Medical Center, Chicago
  • University of Illinois at Chicago, Chicago
  • dan 2 lagi
Semua umur · Semua jantina · Dikemas kini 6 Jul 2026 · NCT01351545

Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia

Mengambil peserta
  • Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago
Umur 14 ke atas · Semua jantina · Dikemas kini 30 Jun 2026 · NCT03932903

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

Mengambil pesertaFasa 1
  • University of Chicago Medical Center, Chicago
Umur 18 hingga 39 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT03571321

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

Mengambil pesertaFasa 2
  • University of Chicago Medical Center, Chicago
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Jun 2026 · NCT04747912

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

Mengambil pesertaKajian pemerhatian
  • Lurie Children's Hospital-Chicago, Chicago
Semua umur · Semua jantina · Dikemas kini 18 Mei 2026 · NCT01790152

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Mengambil pesertaFasa 1
  • University of Chicago, Chicago
Umur 13 ke atas · Semua jantina · Dikemas kini 5 Mei 2026 · NCT04771572

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Mengambil pesertaFasa 1/2
  • Northwestern, Chicago
Umur 12 ke atas · Semua jantina · Dikemas kini 24 Mac 2026 · NCT04988555

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Mengambil pesertaFasa 1/2
  • University of Chicago Medicine Comprehensive Cancer Center, Chicago
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Mac 2026 · NCT06207123

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Mengambil pesertaFasa 2
  • University of Chicago Comprehensive Cancer Center, Chicago
Umur 18 hingga 54 · Semua jantina · Dikemas kini 17 Mac 2026 · NCT06918431

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Mengambil pesertaFasa 1
  • Ann & Robert H Lurie Children's Hospital of Chicago, Chicago
Umur 1 hingga 40 · Semua jantina · Dikemas kini 12 Mac 2026 · NCT05292664

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Mengambil pesertaFasa 1
  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Umur 1 hingga 21 · Semua jantina · Dikemas kini 6 Dis 2024 · NCT05476770

Kajian Leukemia Limfoblastik Akut di bandar lain

Kajian lain di Chicago

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.